Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy

European Journal of Cancer

Volumn 43, Issue 1, 2007, Pages 137-143

  Casula, Milena ^a   Colombino, Maria ^a   Satta, Maria P ^a   Cossu, Antonio ^b   Lissia, Amelia ^b   Budroni, Mario ^c   Simeone, Ester ^d   Calemma, Rosa ^d   Loddo, Cinzia ^d   Caracò, Corrado ^d   Mozzillo, Nicola ^d   Daponte, Antonio ^d   Comella, Giuseppe ^d   Canzanella, Sergio ^e   Guida, Michele ^f   Castello, Giuseppe ^d   Ascierto, Paolo A ^d   Palmieri, Giuseppe ^a  

^a Istituto di Chimica Biomolecolare Consiglio Nazionale Ricerche   (Italy)

^b Azienda USL 1   (Italy)

^c Centro Epidemiologico Multizonale   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e Associazione House Hospital Onlus   (Italy)

^f NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Cancer genes; Genetic testing; Mutation analysis; Polymerase chain reaction

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BRAF GENE; BRCA2 GENE; CANCER GENETICS; CANCER RECURRENCE; CANCER RISK; CDKN2A GENE; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DNA SEQUENCE; FAMILIAL CANCER; FEMALE; GENE; GENE MUTATION; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; GEOGRAPHIC DISTRIBUTION; GERM LINE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MUTATION RATE; ONSET AGE; PATIENT COUNSELING; POPULATION RESEARCH; PRIORITY JOURNAL;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, BRCA2; GENES, P16; GENETIC SCREENING; GERM-LINE MUTATION; HUMANS; ITALY; MALE; MELANOMA; MIDDLE AGED; PROTO-ONCOGENE PROTEINS B-RAF; REGRESSION ANALYSIS; SKIN NEOPLASMS;

EID: 33846127796     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.07.017     Document Type: Article

References (36)

1. Parkin D.M., Whelan S.L., Ferlay J., et al. Cancer incidence in five continents Vol. VIII (2003), IARC Press, Lyon, France
2. Gilchrest B.A., Eller M.S., Geller A.C., and Yaar M. The pathogenesis of melanoma induced by ultraviolet radiation. New Engl J Med 340 (1999) 1341-1348
3. Jhappan C., Noonan F.P., and Merlino G. Ultraviolet radiation and cutaneous malignant melanoma. Oncogene 22 (2003) 3099-3112
4. Thompson J.F., Scolyer R.A., and Kefford R.F. Cutaneous melanoma. The Lancet 365 (2005) 687-701
5. Haluska F.G., and Hodi F.S. Molecular genetics of familial cutaneous melanoma. J Clin Oncol 16 (1998) 670-682
6. Bataille V. Genetic epidemiology of melanoma. Eur J Cancer 39 (2003) 1341-1347
7. Hayward N.K. Genetics of melanoma predisposition. Oncogene 22 (2003) 3053-3062
8. Wang Y.L., Uhara H., Yamazaki Y., et al. Immunohistochemical detection of CDK4 and p16INK4 proteins in cutaneous malignant melanoma. Br J Dermatol 134 (1996) 269-275
9. Sharpless E., and Chin L. The INK4a/ARF locus and melanoma. Oncogene 22 (2003) 3092-3098
10. Bennett D.C. Human melanocyte senescence and melanoma susceptibility genes. Oncogene 22 (2003) 3063-3069
11. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
12. Casula M., Colombino M., Satta M.P., et al. BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility. J Clin Oncol 22 (2004) 286-292
13. E600-associated senescence-like cell cycle arrest of human naevi. Nature 436 (2005) 720-724
14. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91:1310-1316.
15. Thompson D., and Easton D. Breast Cancer Linkage Consortium: Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68 (2001) 410-419
16. Bishop D.T., Demenais F., Goldstein A.M., et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 94 (2002) 894-903
17. Budroni M, Tanda F. Registro Tumori della Provincia di Sassari I tumori in Sardegna negli anni novanta. Tipografia Moderna, Sassari, Italy 2002;9-22.
18. Mantelli M., Barile M., Ciotti P., et al. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families. Am J Med Genet 107 (2002) 214-217
19. Della Torre G., Pasini B., Frigerio S., et al. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation. Br J Cancer 85 (2001) 836-842
20. Monzon J., Liu L., Brill H., et al. Mutations in multiple primary melanomas. N Engl J Med 338 (1998) 879-887
21. Hashemi J., Platz A., Ueno T., et al. CDKN2A germline mutations in individuals with multiple cutaneous melanomas. Cancer Res 60 (2000) 6864-6867
22. Puig S., Malvehy J., Badenas C., et al. Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol 23 (2005) 3043-3051
23. Palomba G., Pisano M., Cossu A., et al. Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian breast cancer patients through a hospital-based screening. Cancer 104 (2005) 1172-1179
24. Palmieri G., Palomba G., Cossu A., et al. BRCA1 and BRCA2 germline mutations in Sardinian breast cancer families and their implications for genetic counseling. Ann Oncol 13 (2002) 1899-1907
25. Liede A., Karlan B.Y., and Narod S.A. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22 (2004) 735-742
26. MacKie R.M., Andrew N., Lanyon W.G., et al. CDKN2A germline mutations in UK patients with familial melanoma and multiple primary melanomas. J Invest Dermatol 111 (1998) 269-272
27. Piepkorn M. Melanoma genetics: An update with focus on the CDKN2A(p16)/ARF tumor suppressors. J Am Acad Dermatol 42 (2000) 705-722
28. Rutter J.L., Bromley C.M., Goldstein A.M., et al. Heterogeneity of risk for melanoma and pancreatic and digestive malignancies: a melanoma case-control study. Cancer 101 (2004) 2809-2816
29. FitzGerald M.G., Harkin D.P., Silva-Arrieta S., et al. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci U S A 93 (1996) 8541-8545
30. Niendorf K, Goggins W, Yang G, et al. MELPREDICT: A logistic regression model to estimate CDKN2A carrier probability. J Med Genet 2005, [Epub ahead of print].
31. Pollock P.M., Pearson J.V., and Hayward N.K. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosom Cancer 15 (1996) 77-88
32. Smith-Sorenson B., and Hoving E. CDKN2A [P16(INK4A)] somatic and germline mutations. Hum Mutat 7 (1996) 294-303
33. Foulkes W.D., Flanders T.Y., Pollock P.M., and Hayward N.K. The CDKN2A (p16) gene and human cancer. Molec Med 3 (1997) 5-20
34. Casula M., Ascierto P.A., Cossu A., et al. Mutation analysis of candidate genes in melanoma-prone families: evidences of different pathogenetic mechanisms at chromosome 9p21. Melanoma Res 13 (2003) 571-579
35. Mantelli M., Pastorino L., Ghiorzo P., et al. Frequency of CDKN2A mutation in Ligurian non-familial melanoma patients. Third Research Meeting on Melanoma, Milan, Italy. Melanoma Res 14 (2004) 77-84
36. Mantelli M., Pastorino L., Ghiorzo P., et al. Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients. Melanoma Res 14 (2004) 443-448